QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VII Benefit-Risk Evaluation in the PSUR

Test your understanding of the concepts covered by GVP Module VII: Benefit-Risk Evaluation in the PSUR.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the principal value of distinguishing a population-specific difference from an apparent difference caused by exposure or reporting patterns?

It prevents any subgroup analysis from being performed It helps ensure that regulatory conclusions and risk minimisation target a genuine clinical difference rather than an artefact It allows the overall product-level conclusion to replace all subgroup evaluation It establishes causality whenever reporting differs between populations

Question 2 of 10 Which finding would most clearly justify reassessment of an existing favourable benefit-risk conclusion?

A minor increase in reports with no change in exposure, seriousness or clinical pattern Evidence that an important risk affects a broader population and is less preventable than previously understood A formatting change in the product information The absence of a new validated signal despite continued monitoring

Question 3 of 10 Which statement best characterises a valid 'benefit-risk balance remains favourable' conclusion?

It is acceptable whenever no new formal signal was validated It should demonstrate that relevant new information was reviewed and explain why it does not materially alter the balance It means that no new safety information was identified It requires proving that every potential risk has been excluded

Question 4 of 10 A post-authorisation study reports a smaller treatment effect than the pivotal trials. What should the PSUR assessment primarily determine?

Whether the post-authorisation estimate should automatically replace the pivotal-trial estimate Whether differences in population, endpoint, adherence, comparator, follow-up or confounding explain the finding and materially change confidence in benefit Whether the pivotal trials should be excluded because they are older Whether the smaller estimate can be ignored if it is not statistically significant

Question 5 of 10 What is the main weakness of a PSUR that presents a sophisticated numerical model without explaining its assumptions or clinical meaning?

Numerical methods are prohibited in benefit-risk evaluation The model may appear precise while its weighting, assumptions and interpretation remain opaque Numerical methods can only evaluate risks and not benefits A qualitative narrative is always legally mandatory instead

Question 6 of 10 Which activity best demonstrates substantive QPPV oversight of a PSUR benefit-risk conclusion?

Signing the final document without reviewing the underlying rationale Personally reproducing every statistical analysis in the PSUR Challenging whether major safety issues, uncertainties, indication differences, RMP implications and proposed actions are adequately addressed Delegating all benefit-risk questions to the product-information function

Question 7 of 10 A monitoring programme is widely distributed, but data show that healthcare professionals rarely follow the required monitoring schedule. What is the most appropriate interpretation?

The risk is controlled because the programme has been distributed The underlying pharmacological hazard no longer needs consideration Poor implementation may increase the practical risk and should be considered in the evaluation The monitoring programme should be treated as evidence of benefit

Question 8 of 10 What is the primary purpose of the integrated benefit-risk evaluation in a PSUR?

To reproduce the detailed safety listings presented in earlier PSUR sections To integrate key benefits, risks, clinical context and uncertainty into a regulatory conclusion To calculate a universal numerical ratio between efficacy and adverse-event frequency To summarise only newly identified safety signals from the reporting interval

Question 9 of 10 Which sequence best represents a defensible benefit-risk assessment process?

Draft conclusion, select supporting data, then document actions Count reports, calculate a ratio, then decide whether benefits matter Define context, identify benefits and risks, review evidence, characterise uncertainty, integrate, conclude and determine implications Review product information, copy the previous conclusion and submit the PSUR

Question 10 of 10 A medicine is authorised for two indications. The benefit is substantial in one indication but modest in the other, while the principal serious risk is similar. What is the most appropriate PSUR approach?

Present one product-level conclusion because the risk is shared Evaluate and present the benefit-risk balance separately by indication Exclude the risk from the indication with the greater benefit Use the indication with the largest patient population as the basis for the overall conclusion

Knowledge Assessment: GVP Module VII Benefit-Risk Evaluation in the PSUR

Cookie Settings